News und Analysen
QIAGEN and DiaSorin Receive FDA Approval for The LIAISON QuantiFERON-TB Gold Plus Test on LIAISON Platforms and Begin Commercial Launch
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the U.S. launch of an automated workflow for QuantiFERON-TB Plus (QFT-Plus), the fourth-generation
QIAGEN und DiaSorin starten Markteinführung nach FDA-Zulassung für LIAISON QuantiFERON-TB Gold Plus Test auf LIAISON-Plattformen
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) und DiaSorin (FTSE Italia Mid Cap: DIA) gaben heute die US-Markteinführung eines automatisierten Workflows für QuantiFERON-TB Plus (QFT-Plus), den
Veeva Announces Fiscal 2020 Third Quarter Results
Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fiscal third quarter ended October 31, 2019.
Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, will be presenting at the Evercore ISI HealthCONx conference on Wednesday, December 4, 2019 at 2:20 PM ET / 11:20 AM PT at the Four
EOS imaging Announces the Upcoming Launch of EOSedge™, Its New Generation Imaging System
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005639/en/
(Photo: Business Wire)
EOS imaging (Paris:EOSI)
Mountain View Medical Group Signs New In-Network Agreement with Humana
Humana Inc. (NYSE: HUM), a leading health and well-being company, has reached an agreement that provides its members in-network access to Mountain View Medical Group in Colorado Springs.
This
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:
-
Steven Pacelli, Executive Vice President, Strategy
Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial
Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today
Agilent Receives Multiple Life Science Industry Awards for Innovation
Agilent Technologies Inc. (NYSE: A) announced today that it has received two Life Science Industry Awards (LSIA) for ‘Most Innovative New Products in 2019’ from BioInformatics Inc. Since 2002, the
Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference
Novocure (NASDAQ: NVCR) announced today that William Doyle, Novocure’s Executive Chairman, will participate in the Evercore ISI 2019 HealthCONx Conference on December 5, 2019, in Boston. Mr
Vifor Pharma raises awareness on Iron Deficiency Day 2019 for people around the world to take iron seriously
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005728/en/
Iron Deficiency Day is an international event which
VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA Associated Vasculitis
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005734/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Agilent Technologies Reports Fourth-Quarter and Fiscal Year 2019 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.37 billion for the fourth quarter ended Oct. 31, 2019, up 6% year over year (core(1) growth of 4%).
On a GAAP basis
NanoString to Present at the Evercore ISI 2nd Annual HealthCONx Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is
Humana Honored for Hispanic Inclusion Efforts
Humana Inc. (NYSE: HUM) has again scored well in the HACR Corporate Inclusion Index, an annual survey by the Hispanic Association on Corporate Responsibility that measures companies’ business
Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today
Humana and Epione Health Team Up to Offer a Patient-Centered Experience for Humana Medicare Advantage Members in Oklahoma
Humana Inc. (NYSE: HUM), a leading health and well-being company, today announced it has collaborated with Epione Health of Oklahoma, LLC on a value-based agreement designed to offer a coordinated
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
ArQule, Inc. (Nasdaq: ARQL) today announced that final clinical data from the company-sponsored phase 1 study of ARQ 531 will be presented on December 9, 2019 at the 61st American Society of
The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion
The Medicines Company (NASDAQ: MDCO) announced today that it has entered into definitive agreement in which Novartis AG will acquire The Medicines Company for $85 per share in an all-cash
SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the extension of the current marketing authorization of SOLIRIS®
Agilent Companion Diagnostic Expands CE-IVD mark in Europe to include Head and Neck Squamous Cell Carcinoma (HNSCC)
Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx assay is now labeled for use in HNSCC in the European Union.
The assay is CE-IVD–marked as an aid in
Lantheus Holdings to Present at the 31st Annual Piper Jaffray Healthcare Conference
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of
Humana Improves Health and Reduces $3.5 Billion in Health Care Costs through Medicare Advantage Value-Based Care Programs
Helping people living with multiple chronic conditions achieve their optimal whole-person health has been a strategic initiative for Humana Inc. (NYSE: HUM). Today, Humana announced that the
Agilent Announces Applications Open for LabCentral Golden Ticket
Agilent Technologies Inc. (NYSE: A) has announced that the nomination process to submit proposals to receive an Agilent-sponsored LabCentral Golden Ticket is open for interested life sciences and